Orchid Pharma has scheduled an investor roadshow in Mumbai from September 28 to 30, 2026. The company announced the event in a filing with the National Stock Exchange of India Limited and BSE Limited on September 21, 2026.

Mridul Dhanuka, Whole Time Director of the company, will participate in the meetings. The roadshow is structured as a series of physical group meets.

Roadshow Schedule

The company outlined the specific dates and format for the upcoming engagement with investors.

The company noted that the schedule may change due to unforeseen exigencies on the part of investors or the company. Any changes will be communicated if they occur.

Regulatory Disclosure

The intimation was issued pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Kapil Dayya, Company Secretary and Compliance Officer, signed the filing. He confirmed that no Unpublished Price Sensitive Information is proposed to be shared during the investor meet.

Orchid Pharma has scheduled its 33rd Annual General Meeting for September 29, 2026. The meeting will address the ratification of a ₹400 crore related-party transaction limit with Otsuka Chemicals (India) Private Limited and the appointment of Mr. Arjun Dhanuka as Whole-Time Director.

The Board convened on September 3, 2026, to approve these matters in compliance with SEBI Listing Regulations. The AGM will be held via Video Conferencing/Other Audio Visual Means (VC/OAVM). The Annual Report for FY25-26, containing the notice, was dispatched to members as on September 4, 2026.

Related Party Transaction Approval

Shareholders are asked to approve material related-party transactions with M/s. Otsuka Chemicals (India) Private Limited for FY27. The proposed ceiling is ₹400 crore for the purchase of goods, specifically the key raw material GCLE (Advanced Cephalosporin Drug Intermediate).

Otsuka is the sole approved source for GCLE. The relationship arises because Mr. Manish Dhanuka (Managing Director) and Mr. Mridul Dhanuka (Whole-Time Director) are directors/members of Otsuka. Transactions in Q1FY26 stood at ₹6,317.48 lakh, while total FY25-26 purchases were ₹24,498 lakh.

Leadership Appointments

Mr. Arjun Dhanuka will serve as Whole-Time Director from September 3, 2026, to September 2, 2031. His monthly salary is set at ₹8 lakh with a 10% annual increment. He previously served as a Non-Executive Non-Independent Director.

Additionally, Mr. Mridul Dhanuka retires by rotation and offers himself for reappointment as Whole-Time Director.

Cost Auditor & Logistics

M/s. J Karthikeyan & Associates was appointed as Cost Auditor for FY27. Shareholders must ratify their remuneration of ₹3.5 lakh plus taxes.

The remote e-voting window opens on September 26, 2026, at 9:00 am and closes on September 28, 2026, at 5:00 pm. The record date for voting eligibility is September 22, 2026.